atrasentan has been researched along with Diabetic Neuropathies in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Calzadilla, SV; Dayton, BD; Jarvis, MF; Kowaluk, EA; Lynch, JJ; Opgenorth, TJ; Padley, RJ; Wessale, JL; Zhu, CZ | 1 |
1 other study(ies) available for atrasentan and Diabetic Neuropathies
| Article | Year |
|---|---|
ABT-627, an endothelin ET(A) receptor-selective antagonist, attenuates tactile allodynia in a diabetic rat model of neuropathic pain.
Topics: Analgesics, Non-Narcotic; Animals; Atrasentan; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Endothelin Receptor Antagonists; Humans; Male; Pain; Pain Measurement; Physical Stimulation; Pyrrolidines; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Receptor, Endothelin B; Stereoisomerism; Vasoconstrictor Agents | 2000 |